According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM ) is €0.16 Billion. In 2023 the company made a revenue of €54.53 Million an increase over the revenue in the year 2022 that were of €25.3 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.